RayKnowChina Research Map
Shortlist

FuzhouFujian Medical University

Fujian Medical University Union Hospital

福建医科大学附属协和医院

Listed for 23 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Fujian Medical University Union Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌49 papers led4 open trials led
  3. Hepatocellular carcinoma肝细胞癌47 papers led
  4. Stomach cancer胃癌166 papers led12 open trials led
  5. Osteosarcoma骨肉瘤0 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤13 papers led2 open trials led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Multiple myeloma多发性骨髓瘤6 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  10. Aplastic anaemia再生障碍性贫血2 papers led
  11. Haemophilia A血友病 A6 papers led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  13. Fanconi anaemia范可尼贫血1 paper led
  14. Myasthenia gravis重症肌无力0 papers led
  15. Moyamoya disease烟雾病4 papers led
  16. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  17. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  18. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症11 papers led
  20. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  21. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  22. IgA nephropathyIgA 肾病0 papers led
  23. Hirschsprung disease先天性巨结肠1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder, IgG4-related disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

5 hospitals in Fuzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  2. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  3. Not yet recruiting
    Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04215510

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryRadiation oncology
Papers it led3
  1. CDCP1 promotes the malignant phenotypes of nasopharyngeal carcinoma via the Wnt/β-catenin signaling pathway.2025BMC biotechnologyFree full text
  2. Research on the changes in the disease burden of nasopharyngeal carcinoma caused by global occupational formaldehyde exposure from 1990 to 2021 and prediction of future trends.2025Frontiers in public healthFree full text
  3. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.2021Applied immunohistochemistry & molecular morphology : AIMM
All its trials on ClinicalTrials.gov, any status12
  1. Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Study sitePhase 3Start 2024-06
  2. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPCRecruitingNCT06235203Study sitePhase 3Start 2024-07
  3. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRTNot yet recruitingNCT04215510Study sitePhase 3Start 2021-03
  4. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Study sitePhase 2Start 2022-05
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  6. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic ImagesStatus unknownNCT05627310Study siteStart 2022-11
  7. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal CarcinomaCompletedNCT04823468Study siteN/AStart 2021-07
  8. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05011227Study sitePhase 2Start 2021-08
  9. A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma PatientsStatus unknownNCT04061278Study sitePhase 3Start 2019-08
  10. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  11. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  12. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)7
  1. LBA103 Early versus routine oral nutritional supplements during concurrent chemoradiotherapy for nasopharyngeal carcinoma: Efficacy and cost-utility analysis in a multicenter randomized controlled trial2025Annals of Oncologyconference-abstract
  2. Post‑irradiation mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy: A large‑cohort and long‑term study2025Oncology Lettersarticle
  3. Validation and Development of a Refined M1 Category for Nasopharyngeal Carcinoma Based on the Ninth-Version of AJCC/UICC TNM Staging System in the Immunotherapy Era: A Multicenter Cohort Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  4. Detection of cytotoxic effects of carboplatin in human nasopharyngeal carcinoma epithelioid cell line CNE-1 by Raman spectroscopy combined with multivariate statistical analysis2024Spectroscopy Lettersarticle
  5. Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.2024Journal of Clinical Oncologyconference-abstract
  6. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  7. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 49 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
49
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 131320222023: 5520232024: 8820242025: 18182025

5 hospitals in Fuzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06510660

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  2. Recruiting
    Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06601309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  3. Recruiting
    Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
    Phase
    N/A
    Started
    2023-05
    Registry
    NCT03734952

    Age 18 years to 65 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  4. Not yet recruiting
    A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07788001

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersRadiation oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led49
  1. SRRN: A regional lymph node ratio-based staging system enhancing prognostic accuracy in esophageal squamous cell carcinoma.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.2026International journal of surgery (London, England)Free full text
  3. Spatial metrics of lymph node metastasis refine prognostic stratification of T1-T2 esophageal squamous cell carcinoma.2026The Journal of thoracic and cardiovascular surgery
  4. Severe postoperative complications after minimally invasive esophagectomy reduce the long-term prognosis of well-immunonutrition patients with locally advanced esophageal squamous cell carcinoma.2025Annals of medicineFree full text
  5. Preoperative immune prognostic index predicts the prognosis and postoperative adjuvant chemotherapy benefits of esophageal squamous cell carcinoma after minimally invasive esophagectomy.2025BMC gastroenterologyFree full text
  6. Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy.2025Cancer medicineFree full text
  7. Prediction of T2/T3 Staging in Patients with Volume-Equivalent Esophageal Squamous Cell Carcinoma on the Basis of PET/CT Radiomics.2025Computer methods and programs in biomedicine
  8. A novel nomogram for predicting long-term survival in patients with esophageal squamous cell carcinoma after minimally invasive esophagectomy.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Comparison of long-term outcomes of 2.5- and 3-field lymph node dissections for esophageal squamous cell carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. The role of pathological response in predicting the benefit of adjuvant therapy after neoadjuvant chemoimmunotherapy in patients with esophageal cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. Hsa_circRNA_0101125 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Carcinoma via miR-143-3p/ZNF148 Axis.2025FASEB journal : official publication of the Federation of American Societies for Experimental BiologyFree full text
  13. The neoadjuvant esophageal score: a prognostic tool for predicting survival and postoperative complications in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  14. Establishment and validation of survival nomogram score staging for esophageal squamous cell carcinoma patients after minimally invasive surgery combined with immune prognostic index and clinicopathological features.2025Frontiers in immunologyFree full text
  15. Application of machine learning based on habitat imaging and vision transformer to predict treatment response of locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a multi-center study.2025Frontiers in immunologyFree full text
  16. The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study.2025Frontiers in immunologyFree full text
  17. Identification of disulfidptosis in esophageal squamous cell carcinoma based on single-cell and bulk RNA-seq data to predict prognosis and treatment response.2025Frontiers in immunologyFree full text
  18. Preoperative albumin-to-fibrinogen ratio as a predictor of postoperative hospital stay in locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy.2025Scientific reportsFree full text
  19. Impact of clinical decisions on patient outcomes after neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma.2025Surgical endoscopy
  20. The enhanced pathological response from additional immunotherapy improved recurrence-free survival for esophageal squamous cell carcinoma: a multi-center cohort study.2025Surgical endoscopy
  21. Impact of Interval to Esophagectomy After Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Cohort Analysis.2025Thoracic cancerFree full text
  22. Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial.2024BMJ openFree full text
  23. BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation.2024Cancer letters
  24. LncRNA LUESCC promotes esophageal squamous cell carcinoma by targeting the miR-6785-5p/NRSN2 axis.2024Cellular and molecular life sciences : CMLSFree full text
  25. Prognostic value of immunosuppression scores in patients with esophageal squamous cell carcinoma: a multicenter study.2024Frontiers in immunologyFree full text
  26. Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study.2024Frontiers in immunologyFree full text
  27. SORBS2-Mediated inhibition of malignant behaviors in esophageal squamous cell carcinoma through TIMP3.2024International immunopharmacology
  28. Elucidating the role of CYFIP2 in conferring cisplatin resistance in esophageal squamous cell carcinoma.2024Scientific reportsFree full text
  29. Comparison of indocyanine green-near-infrared fluorescence guided and traditional mediastinal lymphadenectomy during radical esophagectomy: A randomized controlled trial.2024SurgeryRCT
  30. Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.2023International journal of clinical oncology
  31. Impact of minimally invasive total mesoesophageal excision and minimally invasive esophagectomy on failure patterns of locally advanced esophageal squamous cell carcinoma: a matched cohort study with long-term follow-up.2023Surgical endoscopy
  32. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.2023TrialsFree full text
  33. Inflammatory and Nutritional Status Influences Outcomes of Minimally Invasive Esophagectomy.2023World journal of surgery
  34. Prediction of pulmonary metastasis in esophageal carcinoma patients with indeterminate pulmonary nodules.2023World journal of surgical oncologyFree full text
  35. Recurrence index predicts the prognosis of patients with pathological T1 esophageal squamous cell carcinoma.2022Asian journal of surgery
  36. Prognostic variables for conditional survival in patients with esophageal squamous cell carcinoma who underwent minimally invasive surgery.2022BMC cancerFree full text
  37. Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial.2022BMJ openFree full text
  38. PolyC-RNA-binding protein 1 (PCBP1) enhances tropomyosin 3 (TPM3) mRNA stability to promote the progression of esophageal squamous cell carcinoma.2022BioengineeredFree full text
  39. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.2022Frontiers in immunologyFree full text
  40. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?2022Frontiers in immunologyFree full text
  41. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.2022Frontiers in immunologyFree full text
  42. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.2022Frontiers in public healthFree full text
  43. Development and validation of a nomogram for preoperative prediction of lymph node metastasis in pathological T1 esophageal squamous cell carcinoma.2022MedicineFree full text
  44. Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis.2022Molecular cancerFree full text
  45. iTRAQ and two-dimensional-LC-MS/MS reveal NAA10 is a potential biomarker in esophageal squamous cell carcinoma.2022Proteomics. Clinical applications
  46. Nomogram for prognosis of patients with esophageal squamous cell cancer after minimally invasive esophagectomy established based on non-textbook outcome.2022Surgical endoscopyRCT
  47. Prognostic Value of Carcinoembryonic Antigen Changes Before and After Operation for Esophageal Squamous Cell Carcinoma.2022World journal of surgery
  48. Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma.2021Clinica chimica acta; international journal of clinical chemistry
  49. Associations of interleukin-4 and interleukin-4 receptor loci with esophageal squamous cell carcinoma susceptibility.2021International immunopharmacology
All its trials on ClinicalTrials.gov, any status17
  1. A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal CancerNot yet recruitingNCT07788001Lead sponsorPhase 3Start 2026-10
  2. Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Lead sponsorPhase 2Start 2024-07
  3. Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingNCT06510660Lead sponsorPhase 2Start 2024-04
  4. Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant ChemoradiotherapyRecruitingNCT03734952Lead sponsorN/AStart 2023-05
  5. Tumor Regression Grade As Predictor of Adjuvant TherapyStatus unknownNCT06710665Lead sponsorStart 2024-10
  6. Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical ResectionStatus unknownNCT06161909Lead sponsorPhase 3Start 2024-01
  7. Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal CarcinomaStatus unknownNCT05821452Lead sponsorPhase 2Start 2023-05
  8. Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.Active, not recruitingNCT05176002Lead sponsorPhase 1/Phase 2Start 2021-11
  9. Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal CarcinomaCompletedNCT04009265Lead sponsorPhase 3Start 2019-08
  10. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  11. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04974047Study sitePhase 2Start 2021-08
  12. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  13. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  14. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  15. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  16. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell CarcinomaCompletedNCT02395705Study sitePhase 3Start 2015-06
  17. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)33
  1. 112. PREOPERATIVE IMMUNE PROGNOSTIC INDEX PREDICTS PROGNOSIS AND POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFITS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER MINIMALLY INVASIVE ESOPHAGECTOMY2025Diseases of the Esophagusarticle
  2. 136. IDENTIFICATION OF ZINC FINGER PROTEIN-RELATED GENES AS PROGNOSTIC INDICATORS AND PREDICTOR OF IMMUNETHERAPY RESPONSE FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  3. 230. IMPACT OF CLINICAL DECISIONS ON PATIENT OUTCOMES AFTER NEOADJUVANT THERAPY IN LOCALLY ADVANCED RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  4. 231. THE ROLE OF TUMOR REGRESSION GRADE IN PREDICTING THE BENEFIT OF ADJUVANT THERAPY FOLLOWING NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY2025Diseases of the Esophagusarticle
  5. 233. COMPARISON OF POSTOPERATIVE ADJUVANT THERAPY AND SURGERY ALONE IN PATHOLOGICAL N1–2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL2025Diseases of the Esophagusarticle
  6. 234. THE APPLICATION OF A NOVEL SPLIT TYPE ROBOTIC SYSTEM CARINA™ PLATFORM FOR ESOPHAGEAL SURGERY2025Diseases of the Esophagusarticle
  7. 236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  8. 237. IMPACT OF LYMPH NODE DISSECTION ON PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS UNDERGOING NEOADJUVANT CHEMOIMMUNOTHERAPY FOLLOWED BY RADICAL SURGERY2025Diseases of the Esophagusarticle
  9. 242. BASELINE 18F-FDG PET/CT SUVMAX AS A PROGNOSTIC INDICATOR FOR LONG-TERM SURVIVAL IN POSTOPERATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  10. 247. BASELINE 18F-FDG PET/CT SUVMAX AS A PROGNOSTIC INDICATOR FOR LONG-TERM SURVIVAL IN POSTOPERATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagusarticle
  11. 274. INDUCTION THERAPIES FOR LOCALLY ADVANCED MARGINALLY RESECTABLE AND UNRESECTABLE ESCC AND CONVERSION SURGERY PROGNOSIS: A REAL-WORLD STUDY2025Diseases of the Esophagusarticle
  12. 326. LYMPH NODE METASTASIS PATTERNS IN T1-T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A NOVEL REGIONAL DIVISION OF LYMPH NODES2025Diseases of the Esophagusarticle
  13. Adjuvant Sintilimab Therapy for High-Risk Recurrent Esophageal Squamous Cell Carcinoma after Radical Resection: A Multicenter Randomized Controlled Clinical Trial Protocol2025Research Squarepreprint
  14. Comparison of different induction therapy for locally advanced marginal resectable and unresectable esophageal squamous cell carcinoma and the prognostic value of subsequent conversion surgery: A real world study.2025Journal of Clinical Oncologyarticle
  15. Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial.2025Journal of Clinical Oncologyconference-abstract
  16. Envafolimab combined with albumin-bound paclitaxel and cisplatin in the neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, multicenter phase II study.2025Journal of Clinical Oncologyarticle
  17. Impact of lymph node dissection on prognosis in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemotherapy and immunotherapy followed by radical surgery.2025Journal of Clinical Oncologyarticle
  18. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial.2025Journal of Clinical Oncologyconference-abstract
  19. The application of a novel split-type robotic system, Carina Platform, for esophageal surgery.2025Journal of Clinical Oncologyarticle
  20. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  21. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncologyconference-abstract
  22. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  23. Tagging polymorphisms in CTLA4 gene with esophageal squamous cell carcinomas: a case-control study2024Research Squarepreprint
  24. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncologyarticle
  25. 20. ADDITIONAL NEOADJUVANT IMMUNOTHERAPY DOESN’T INCREASE THE RISK OF ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY: A MULTICENTER RETROSPECTIVE COHORT STUDY2023Diseases of the Esophagusarticle
  26. 325. CAMRELIZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMORADIOTHERAPY FOR THE CONVERSION OF UNRESECTABLE ESOPHAGEAL CARCINOMA: A PROSPECTIVE CLINICAL STUDY PROTOCOL2023Diseases of the Esophagusarticle
  27. 337. PREDICTION OF PULMONARY METASTASIS IN ESOPHAGEAL CARCINOMA PATIENTS WITH INDETERMINATE2023Diseases of the Esophagusarticle
  28. 339. CYTOPLASMIC TRANSLOCATION OF BCLAF1 REGULATES SIX1 MRNA STABILITY THROUGH YTHDF2 TO PROMOTE AEROBIC GLYCOLYSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagusarticle
  29. 41. HIGH COMPREHENSIVE COMPLICATION INDEX AFTER MINIMALLY INVASIVE ESOPHAGECTOMY ASSOCIATED WITH POOR SHORT-TERM AND LONG-TERM OUTCOME: A PROPENSITY SCORE MATCHING ANALYSIS2023Diseases of the Esophagusarticle
  30. Characteristics of the gut microbiome in patients with Esophageal Squamous Cell Cancer2022Research Squarepreprint
  31. Concurrent Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  32. Predictive value for advanced lung cancer inflammation index within short- /long-term outcomes of esophageal squamous cell carcinoma after minimally invasive esophagectomy cases: a propensity score matching study2022Research Squarepreprint
  33. Development of a Prognostic Nomogram and Risk Stratification System for Upper Thoracic Esophageal Squamous Cell Carcinoma2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 47 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
47
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 4420222023: 121220232024: 121220242025: 12122025

6 hospitals in Fuzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsRecurrence & prognosisImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led47
  1. Lactylated SPTAN1 Accelerates Hepatocellular Carcinoma Progression by Promoting NOTCH1/HES1 Activation and Immunosuppression.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Inhibition of RBPJ transcription complex promotes IL-17 and IFN-γ secretion by CD4⁺ T cells in hepatocellular carcinoma.2025Archives of pharmacal research
  3. Can the detection of serum glutathione reductase serve as an effective complement to traditional tumor biomarkers in clinical laboratory medicine for patients with hepatocellular carcinoma?2025BMC cancerFree full text
  4. New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity.2025British journal of cancerFree full text
  5. Hepatitis B Virus X Protein Upregulates SREBP2 to Modulate Autophagy in Hepatocellular Carcinoma.2025Cancer medicineFree full text
  6. Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus.2025Cardiovascular and interventional radiology
  7. N-glycosylated LTβR increases the Th17/Treg cell ratio in liver cancer by blocking RORC ubiquitination and FOXP3 transcription.2025Cell death & diseaseFree full text
  8. Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  9. tRNA methyltransferase DNMT2 promotes hepatocellular carcinoma progression and enhances Bortezomib resistance through inhibiting TNFSF10.2025Cellular signalling
  10. TCP1 promotes the progression of malignant tumours by stabilizing c-Myc through the AKT/GSK-3β and ERK signalling pathways.2025Communications biologyFree full text
  11. Neurogranin facilitates maintaining the immunosuppressive state of hepatocellular carcinoma by promoting TGF-β1 secretion.2025International journal of biological macromolecules
  12. The Red Cell Distribution Width to Albumin Ratio: A Novel Prognostic Indicator in Hepatitis B Virus-Related Hepatocellular Carcinoma.2025International journal of medical sciencesFree full text
  13. Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer.2025TheranosticsFree full text
  14. Hepatitis B virus X protein differentially regulates the angiogenesis of Hepatocellular Carcinoma through p53-VEGF axis according to glucose levels.2024Annals of hepatology
  15. Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.2024BMJ openFree full text
  16. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  17. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.2024Cellular signalling
  18. YTHDF3-mediated m6A modification of NKD1 regulates hepatocellular carcinoma invasion and metastasis by activating the WNT/β-catenin signaling axis.2024Experimental cell research
  19. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.2024Free radical biology & medicine
  20. Novel prognostic signature for hepatocellular carcinoma using a comprehensive machine learning framework to predict prognosis and guide treatment.2024Frontiers in immunologyFree full text
  21. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.2024Frontiers in public healthFree full text
  22. Laparoscopic liver resection is superior to radiofrequency ablation for small hepatocellular carcinoma: a systematic review and meta-analysis of propensity score-matched studies.2024Hepatology international
  23. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.2024International immunopharmacology
  24. Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio.2024International immunopharmacology
  25. LAIR1 promotes hepatocellular carcinoma cell metastasis and induces M2-macrophage infiltration through activating AKT-IKKβ-p65 axis.2024Molecular carcinogenesis
  26. ASO Author Reflections: The Application of ICG Fluorescent Staining in Laparoscopic Hepatectomy for Liver Malignancies is More Beneficial to Ensure Radical Surgery.2023Annals of surgical oncology
  27. Does Using Indocyanine Green Fluorescence Imaging for Tumors Help in Determining the Safe Surgical Margin in Real-Time Navigation of Laparoscopic Hepatectomy? A Retrospective Study.2023Annals of surgical oncologyFree full text
  28. XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  29. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.2023Brachytherapy
  30. A modified immune cell infiltration score achieves ideal stratification for CD8+ T cell efficacy and immunotherapy benefit in hepatocellular carcinoma.2023Cancer immunology, immunotherapy : CIIFree full text
  31. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.2023Cancer reports (Hoboken, N.J.)Free full text
  32. TGF-β-p-STAT1-LAIR2 axis has a "self-rescue" role for exhausted CD8+ T cells in hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  33. Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8+ T cells in hepatocellular carcinoma.2023Communications biologyFree full text
  34. Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.2023Gene
  35. Red Blood Cell Distribution Width as a Potential Valuable Survival Predictor in Hepatitis B Virus-related Hepatocellular Carcinoma.2023International journal of medical sciencesFree full text
  36. 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.2023Journal for immunotherapy of cancerFree full text
  37. SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape.2023Science signaling
  38. Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells.2022Cancer scienceFree full text
  39. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.2022Cell biology and toxicology
  40. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.2022International journal of experimental pathology
  41. Evaluation of microvascular invasion of hepatocellular carcinoma using whole-lesion histogram analysis with the stretched-exponential diffusion model.2022The British journal of radiologyFree full text
  42. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis.2021Advances in therapy
  43. Clinical characteristics and surgical treatments of primary hepatic angiosarcoma.2021BMC gastroenterologyFree full text
  44. Quantification of Intrafraction and Interfraction Tumor Motion Amplitude and Prediction Error for Different Liver Tumor Trajectories in Cyberknife Synchrony Tracking.2021International journal of radiation oncology, biology, physics
  45. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.2021Life sciences
  46. The Islanding effect - a special method of percutaneous peritumor ethanol injection for hepatocellular carcinoma: 15-year follow-up outcome.2021MedicineFree full text
  47. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.2021Toxicology in vitro : an international journal published in association with BIBRA
All its trials on ClinicalTrials.gov, any status6
  1. Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver CaActive, not recruitingNCT07493070Lead sponsorN/AStart 2026-02
  2. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  3. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  4. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  5. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  6. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 166 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.7%.

Papers led
166
2021–2025
Trials led
48
any status, ClinicalTrials.gov
Open trials led
12
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 333320212022: 232320222023: 262620232024: 393920242025: 43432025

6 hospitals in Fuzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06945718

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  2. Recruiting
    A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05938309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  3. Recruiting
    3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT06161207

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  4. Recruiting
    A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
    Phase
    N/A
    Started
    2023-01
    Registry
    NCT06277024

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  5. Recruiting
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05618821

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  6. Recruiting
    Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
    Phase
    Not given
    Started
    2018-10
    Registry
    NCT03716089

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  7. Not yet recruiting
    Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07314203

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  8. Not yet recruiting
    the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
    Phase
    N/A
    Started
    2022-02
    Registry
    NCT05235932

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  9. Not yet recruiting
    Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05524974

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  10. Not yet recruiting
    Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05610332

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  11. Not yet recruiting
    Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2021-03
    Registry
    NCT04795063

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  12. Enrolling by invitation
    Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Early phase 1
    Started
    2025-05
    Registry
    NCT07356466

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  13. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  14. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  15. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

  16. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  17. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryChemotherapy & combined treatmentPeritoneal spread & advanced disease
Departments in papersMedical oncologyRadiology / nuclear medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led166
  1. NCAPD2 Modulates MHC-I Antigen Presentation via the PI3K/AKT Axis to Drive Metastatic Progression in Gastric Cancer.2026Digestive diseases and sciences
  2. Identifying chemotherapy benefits in high-risk patients with stage IB gastric cancer based on recurrence prediction value: A multicenter retrospective study.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. A Cascaded Segmentation-Classification Deep Learning Framework for Preoperative Prediction of Occult Peritoneal Metastasis and Early Recurrence in Advanced Gastric Cancer.2025Academic radiology
  4. Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study.2025Annals of medicineFree full text
  5. Machine Learning Prediction of Early Recurrence in Gastric Cancer: A Nationwide Real-World Study.2025Annals of surgical oncology
  6. Clinical Value of Nomograms Integrating Circulating Lipid and Inflammation Risk Score in Predicting Long-Term Outcomes After Radical Gastrectomy in Gastric Cancer: A Multicenter Real-World Study.2025Annals of surgical oncology
  7. Effect of Adjuvant Chemotherapy Cycles on Patients with Node-Negative Gastric Cancer Following Neoadjuvant Chemotherapy: Multicenter Cohort Study.2025Annals of surgical oncology
  8. Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?-A Retrospective Analysis.2025Annals of surgical oncology
  9. Appraisal of Residual Tumor Burden on Survival Prognosis Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Multicenter Cohort Study.2025Annals of surgical oncology
  10. Patterns of Survival and Recurrence in Poor Responders to Neoadjuvant Therapy for Gastric Cancer: A Real-World Multicenter Study.2025Annals of surgical oncology
  11. Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China.2025BMC cancerFree full text
  12. Development and validation of a prognostic prediction model for elderly gastric cancer patients based on oxidative stress biochemical markers.2025BMC cancerFree full text
  13. Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.2025BMC medicineRCTFree full text
  14. Comparison of gastric microbiota in patients with different gastric lesions in high and low risk areas of gastric cancer.2025BMC microbiologyFree full text
  15. Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy.2025Cancer researchFree full text
  16. Targeting LHPP in neoadjuvant chemotherapy resistance of gastric cancer: insights from single-cell and multi-omics data on tumor immune microenvironment and stemness characteristics.2025Cell death & diseaseFree full text
  17. Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials.2025Cell reports. MedicineRCTFree full text
  18. Koumine alters immune barrier function by targeting TGFβ-mediated collagen deposition in gastric cancer.2025European journal of pharmacology
  19. Development of a modified nutritional index model based on nutritional status and sarcopenia to predict long-term survival and chemotherapy benefits in elderly patients with advanced gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  20. Enhancing prognostic accuracy in gastric cancer: The TNrrM staging system versus the AJCC TNM system.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  21. Comparison of short- and mid-term outcomes of robotic versus laparoscopic gastrectomy in high-risk patients with gastric cancer: a nationwide, multicentre cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  22. Surgical and oncological outcomes of laparoscopic versus open gastrectomy after neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  23. Long-term survival analysis after radical gastrectomy for Epstein-Barr virus-associated gastric cancer: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  24. Dynamic postoperative prognosis and follow-up optimization for gastric cancer patients after neoadjuvant therapy: a multicenter retrospective study.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  25. Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  26. A novel ypN-TRG staging system for gastric cancer patients after neoadjuvant therapy based on the metro-ticket paradigm: a multicenter and large sample retrospective analysis.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  27. Exploring the role of OSMR in gastric cancer: from oncogenic functions to relevant immune features.2025International immunopharmacology
  28. Assessment of robotic versus laparoscopic gastrectomy for gastric cancer patients with intraoperative technical complexity: a multicenter retrospective study.2025International journal of surgery (London, England)Free full text
  29. Development and validation of a novel modified cancer cachexia index in patients with locally advanced gastric cancer undergoing neoadjuvant chemotherapy: a multicenter cohort study.2025International journal of surgery (London, England)Free full text
  30. Development of a staging system for hepatoid adenocarcinoma of the stomach based on multicenter data: a retrospective cohort study.2025International journal of surgery (London, England)Free full text
  31. Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy.2025JAMA surgeryFree full text
  32. The impact of surgical case order on short- and long-term outcomes in patients undergoing laparoscopic gastrectomy: a propensity matched study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  33. Multi-cohort study in gastric cancer to develop CT-based radiomic models to predict pathological response to neoadjuvant immunotherapy.2025Journal of translational medicineFree full text
  34. Trend analysis and projection of gastric cancer burden linked to high sodium intake in China, Japan, Republic of Korea, and Mongolia (1990-2021): A comprehensive assessment based on the 2021 global burden of disease study.2025PloS oneFree full text
  35. Trend analysis and projection of the gastric cancer disease burden in Taiwan during 1990-2021: An analysis of the global burden of disease study 2021.2025PloS oneFree full text
  36. Long-term trends and projections of stomach cancer burden in China: Insights from the GBD 2021 study.2025PloS oneFree full text
  37. Comprehensive comparison of technical performance, surgical outcomes, and oncologic prognosis between remnant gastric cancer and primary upper-third gastric cancer in the era of minimally invasive surgery: A pooled analysis of 3 prospective2025Surgery
  38. The minimum number of lymph node retrieval in gastric cancer patients after neoadjuvant therapy: An international multi-institute cohort study.2025Surgery
  39. Textbook oncological outcome of locally advanced gastric cancer patients with preoperative sarcopenia: a multicenter clinical study.2025Surgical endoscopy
  40. Assessment of the safety and efficacy of robotic versus laparoscopic gastrectomy in overweight patients with gastric cancer: a large-scale multicenter cohort study.2025Surgical endoscopy
  41. Predicting the prognosis of radical gastrectomy for patients with locally advanced gastric cancer after neoadjuvant chemotherapy using machine learning technology: a multicenter study in China.2025Surgical endoscopy
  42. Comparison of short- and long-term outcomes for robotic versus laparoscopic gastrectomy in elderly patients with gastric cancer: a multicenter cohort study.2025Surgical endoscopy
  43. Development of a prognostic oxidative stress-immune-inflammation score and online calculators for predicting survival and recurrence in gastric cancer: a multicenter study.2025Surgical endoscopy
  44. Preoperative visceral fat area predicts intraoperative adverse events during lymphadenectomy in laparoscopic gastrectomy for gastric cancer: a post hoc analysis.2025Surgical endoscopyRCT
  45. Impact of visceral fat distribution on postoperative complications in high-aged patients undergoing gastric cancer surgery: A cross-sectional study.2025World journal of gastroenterologyFree full text
  46. Assessment of Laparoscopic Indocyanine Green Tracer-guided Lymphadenectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Controlled Trial.2024Annals of surgeryRCT
  47. Comparison of Short-term and Three-year Oncological Outcomes Between Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Large Multicenter Cohort Study.2024Annals of surgery
  48. Comparison of Short-Term Outcomes After Robotic Versus Laparoscopic Radical Gastrectomy for Advanced Gastric Cancer in Elderly Individuals: A Propensity Score-Matching Study.2024Annals of surgical oncology
  49. Predictive Value of a New Muscle Parameter in Patients with Resectable Gastric Cancer: A Pooled Analysis of Three Prospective Trials.2024Annals of surgical oncologyFree full text
  50. Laparoscopic radical gastrectomy for gastric cancer: Long-term outcome in a teaching center.2024Asian journal of surgery
  51. Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study.2024BMC cancerFree full text
  52. Trajectories of neutrophil-to-lymphocyte ratios during neoadjuvant chemotherapy correlate with short- and long-term outcomes in gastric cancer: a group-based trajectory analysis.2024BMC cancerFree full text
  53. The diagnostic value of two-dimensional ultrasound Su-RADS combined with shear wave elastography for benign and malignant lesions of the gastric wall.2024BMC medical imagingFree full text
  54. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035.2024BMC public healthFree full text
  55. Increased ONECUT2 induced by Helicobacter pylori promotes gastric cancer cell stemness via an AKT-related pathway.2024Cell death & diseaseFree full text
  56. NUAK1 activates STAT5/GLI1/SOX2 signaling to enhance cancer cell expansion and drives chemoresistance in gastric cancer.2024Cell reports
  57. Circ-0075305 hinders gastric cancer stem cells by indirectly disrupting TCF4-β-catenin complex and downregulation of SOX9.2024Communications biologyFree full text
  58. A Preoperative Prediction Model for Lymph Node Metastasis in Patients with Gastric Cancer Using a Machine Learning-based Ultrasomics Approach.2024Current medical imaging
  59. Risk stratification models incorporating oxidative stress factors to predict survival and recurrence in patients with gastric cancer after radical gastrectomy: A real-world multicenter study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  60. Reply to: Chemotherapy benefits in patients with hepatoid adenocarcinoma: A long-term follow-up study on a rare gastric disease.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  61. Effects of tumor marker regression load score on long-term prognosis of gastric cancer patients undergoing radical surgery after neoadjuvant chemotherapy.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  62. Textbook oncological outcomes and prognosis after curative gastrectomy in advanced gastric cancer: A multicenter study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  63. Prognostic value of preoperative sarcopenia in gastric cancer: A 10-year follow-up study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  64. Construction of a nomogram with IrAE and clinic character to predict the survival of advanced G/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment.2024Frontiers in immunologyFree full text
  65. Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion.2024Frontiers in immunologyFree full text
  66. Impact of chemotherapy delay on long-term prognosis of laparoscopic radical surgery for locally advanced gastric cancer: a pooled analysis of four randomized controlled trials.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  67. Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  68. KLHL21 suppresses gastric tumourigenesis via maintaining STAT3 signalling equilibrium in stomach homoeostasis.2024Gut
  69. Enlightenment of robotic gastrectomy from 527 patients with gastric cancer in the minimally invasive era: 5 years of optimizing surgical performance in a high-volume center - a retrospective cohort study.2024International journal of surgery (London, England)Free full text
  70. The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicentre real-world clinical study.2024International journal of surgery (London, England)Free full text
  71. Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial.2024JAMA surgeryRCTFree full text
  72. Exosomes derived from gastric cancer cells promote phenotypic transformation of hepatic stellate cells and affect the malignant behavior of gastric cancer cells.2024Journal of cancer research and therapeutics
  73. Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial.2024Nature communicationsRCTFree full text
  74. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.2024Nature communicationsRCTFree full text
  75. AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK/p-NF-κB signaling pathways.2024Scientific reportsFree full text
  76. Novel nomogram and risk stratification for peritoneal recurrence after curative resection in gastric cancer.2024Scientific reportsFree full text
  77. Effect of sarcopenia on short-term and long-term outcomes of older patients with locally advanced gastric cancer: a multicenter study.2024Surgical endoscopy
  78. Developing a modified textbook outcome for elderly patients with gastric cancer: a multi-center study.2024Surgical endoscopy
  79. Robotic gastrectomy was reliable option for overweight patients with gastric cancer: a propensity score matching study.2024Surgical endoscopy
  80. Robot-assisted versus laparoscopic-assisted gastrectomy among malnourished patients with gastric cancer based on textbook outcome.2024Surgical endoscopy
  81. Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer.2024Surgical endoscopy
  82. BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/β-catenin pathway.2024TheranosticsFree full text
  83. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.2024TheranosticsFree full text
  84. Preoperative prediction of lymphovascular and perineural invasion in gastric cancer using spectral computed tomography imaging and machine learning.2024World journal of gastroenterologyFree full text
  85. Loss of ATOH1 in Pit Cell Drives Stemness and Progression of Gastric Adenocarcinoma by Activating AKT/mTOR Signaling through GAS1.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  86. Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  87. Intraoperative Adverse Events, Technical Performance, and Surgical Outcomes in Laparoscopic Radical Surgery for Gastric Cancer: A Pooled Analysis From 2 Randomized Trials.2023Annals of surgery
  88. Patient-Reported Outcomes of Individuals with Gastric Cancer Undergoing Totally Laparoscopic Versus Laparoscopic-Assisted Total Gastrectomy: A Real-World, Propensity Score-Matching Analysis.2023Annals of surgical oncology
  89. Nomogram to Predict Recurrence and Guide a Pragmatic Surveillance Strategy After Resection of Hepatoid Adenocarcinoma of the Stomach: A Retrospective Multicenter Study.2023Annals of surgical oncology
  90. Value of the Preoperative D-Dimer to Albumin Ratio for Survival and Recurrence Patterns in Gastric Cancer.2023Annals of surgical oncology
  91. ASO Author Reflections: A Recurrence Nomogram to Guide Surveillance Strategies After the Resection of Hepatoid Adenocarcinoma of the Stomach.2023Annals of surgical oncology
  92. Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis.2023BMC cancerFree full text
  93. CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages.2023Cancer gene therapyFree full text
  94. Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real-world retrospective study.2023Cancer medicineFree full text
  95. Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer.2023Cancer research
  96. A scoring model for predicting early recurrence of gastric cancer with normal preoperative tumor markers: A multicenter study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  97. Long-term prognostic benefit of adjuvant chemotherapy for patients with hepatoid adenocarcinoma of the stomach after radical resection: A national multicenter study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  98. The GLIM criteria as an effective tool for survival prediction in gastric cancer patients.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  99. SOX9 Modulates the Transformation of Gastric Stem Cells Through Biased Symmetric Cell Division.2023GastroenterologyFree full text
  100. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.2023GutFree full text
  101. An international multi-institution real-world study of the optimal surveillance frequency for stage II/III gastric cancer: the more, the better?2023International journal of surgery (London, England)RCTFree full text
  102. Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial.2023JAMA surgeryFree full text
  103. Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study from SEER Database.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  104. Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer.2023La Radiologia medica
  105. Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial.2023Nature communicationsRCTFree full text
  106. Short-term outcomes of a new gastrointestinal decompression tube combined with conservative treatment in patients with esophagojejunal anastomotic leakage after total gastrectomy.2023Surgical endoscopy
  107. Comparison of robotic versus laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a prospective trial-based economic evaluation.2023Surgical endoscopy
  108. Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy: a study of real-world data.2023Surgical endoscopy
  109. Silencing Rac1 and Prex1 Inhibit Epithelial-Mesenchymal Transition in Human Gastric Cancer Cells Induced by Transforming Growth Factor-β1.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  110. A Novel ypTLM Staging System Based on LODDS for Gastric Cancer After Neoadjuvant Therapy: Multicenter and Large-Sample Retrospective Study.2023World journal of surgery
  111. Surgical Outcomes, Technical Performance, and Surgery Burden of Robotic Total Gastrectomy for Locally Advanced Gastric Cancer: A Prospective Study.2022Annals of surgery
  112. ASO Author Reflections: Radiomic Immunosuppressive Scoring System for Predicting Prognosis and Chemotherapy Benefit in Gastric Cancer.2022Annals of surgical oncology
  113. Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study.2022Annals of surgical oncology
  114. m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer.2022Cell death & diseaseFree full text
  115. The Therapeutic Effects of Dihydroartemisinin on Cisplatin-Resistant Gastric Cancer Cells.2022Current pharmaceutical biotechnology
  116. Development and validation of metabolic scoring to individually predict prognosis and monitor recurrence early in gastric cancer: A large-sample analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  117. Novel CT based clinical nomogram comparable to radiomics model for identification of occult peritoneal metastasis in advanced gastric cancer.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  118. Textbook outcome, chemotherapy compliance, and prognosis after radical gastrectomy for gastric cancer: A large sample analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  119. A novel hematological classifier predicting chemotherapy benefit and recurrence hazard for locally advanced gastric cancer A multicenter IPTW analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  120. Postoperative follow-up for gastric cancer needs to be individualized according to age, tumour recurrence pattern, and recurrence time.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  121. Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer.2022Frontiers in immunologyFree full text
  122. Helicobacter pylori-induced RASAL2 Through Activation of Nuclear Factor-κB Promotes Gastric Tumorigenesis via β-catenin Signaling Axis.2022GastroenterologyFree full text
  123. Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.2022JAMA network openFree full text
  124. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.2022JAMA surgeryRCTFree full text
  125. Application of an artificial neural network for predicting the potential chemotherapy benefit of patients with gastric cancer after radical surgery.2022SurgeryRCT
  126. Assessment of the short-term outcomes of laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A prospective single-armed clinical trial.2022Surgery
  127. Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching.2022Surgical endoscopyFree full text
  128. A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients.2022Surgical endoscopy
  129. A matched cohort study of the failure pattern after laparoscopic and open gastrectomy for locally advanced gastric cancer: does the operative approach matter?2022Surgical endoscopy
  130. Comparison of long-term outcomes after robotic versus laparoscopic radical gastrectomy: a propensity score-matching study.2022Surgical endoscopy
  131. Robotic spleen-preserving total gastrectomy shows better short-term advantages: a comparative study with laparoscopic surgery.2022Surgical endoscopy
  132. Reciprocity between lymphadenectomy quality and adjuvant chemotherapy compliance in gastric cancer: post hoc analysis of two randomized controlled trials.2022Surgical endoscopy
  133. The peroxisome proliferator-activated receptor agonist rosiglitazone specifically represses tumour metastatic potential in chromatin inaccessibility-mediated FABP4-deficient gastric cancer.2022TheranosticsFree full text
  134. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial.2021Annals of surgeryRCT
  135. Fibrinogen-Albumin Ratio as a New Promising Preoperative Biochemical Marker for Predicting Oncological Outcomes in Gastric Cancer: A Multi-institutional Study.2021Annals of surgical oncology
  136. ASO Author Reflections: Fibrinogen-Albumin Ratio as New Promising Biochemical Marker for Predicting Oncological Outcomes in Gastric Cancer Compared with the Combination of Other Inflammation-Related Factors.2021Annals of surgical oncology
  137. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study.2021Annals of surgical oncology
  138. ASO Author Reflections: Long-Term Efficacy of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer.2021Annals of surgical oncology
  139. BMI-adjusted prognosis of signet ring cell carcinoma in patients undergoing radical gastrectomy for gastric adenocarcinoma.2021Asian journal of surgery
  140. Comparison of submucosal and subserosal approaches toward optimized indocyanine green tracer-guided laparoscopic lymphadenectomy for patients with gastric cancer (FUGES-019): a randomized controlled trial.2021BMC medicineRCTFree full text
  141. Identification of Genes Universally Differentially Expressed in Gastric Cancer.2021BioMed research internationalFree full text
  142. Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.2021Cancer medicineRCTFree full text
  143. Effect of Preoperative Tumor Under-Staging on the Long-term Survival of Patients Undergoing Radical Gastrectomy for Gastric Cancer.2021Cancer research and treatmentFree full text
  144. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.2021Clinical nutrition (Edinburgh, Scotland)
  145. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.2021Current pharmaceutical biotechnology
  146. CT-based radiomics nomogram for preoperative prediction of No.10 lymph nodes metastasis in advanced proximal gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  147. Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.2021Frontiers in immunologyFree full text
  148. Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  149. Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  150. Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  151. LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.2021Human cell
  152. Bioinformatics analysis of the prognosis and biological significance of VCAN in gastric cancer.2021Immunity, inflammation and diseaseFree full text
  153. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.2021International immunopharmacology
  154. Clinical implications of Indocyanine Green Fluorescence Imaging-Guided laparoscopic lymphadenectomy for patients with gastric cancer: A cohort study from two randomized, controlled trials using individual patient data.2021International journal of surgery (London, England)RCT
  155. Outcomes of Laparoscopic Total Gastrectomy Combined With Spleen-Preserving Hilar Lymphadenectomy for Locally Advanced Proximal Gastric Cancer: A Nonrandomized Clinical Trial.2021JAMA network openFree full text
  156. Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach.2021JAMA network openFree full text
  157. Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer.2021JAMA network openFree full text
  158. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.2021JAMA network openFree full text
  159. KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.2021Journal of clinical laboratory analysisFree full text
  160. 5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer.2021Journal of gastroenterology and hepatology
  161. Increased CD44 Expression and MEK Activity Predict Worse Prognosis in Gastric Adenocarcinoma Patients Undergoing Gastrectomy.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  162. Dynamic Changes in Pre- and Postoperative Levels of Inflammatory Markers and Their Effects on the Prognosis of Patients with Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractFree full text
  163. ADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation.2021Life sciences
  164. Does three-dimensional surgery affect recurrence patterns in patients with gastric cancer after laparoscopic R0 gastrectomy? Results from a 3-year follow-up phase III trial.2021Surgical endoscopyRCT
  165. Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopic-assisted and open radical gastrectomy for gastric cancer - A propensity score-matching analysis.2021Surgical oncology
  166. Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study.2021The oncologistFree full text
Chinese-language papers (not in the count)8
  1. [Prognostic significance of textbook outcome in advanced gastric patients who underwent neoadjuvant chemotherapy followed by surgical resection].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Quality control of gastric resection range in laparoscopic locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Prevention and management of complications related to laparoscopic spleen-preserving hilar lymph node dissection for gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Effect of splenic hilar lymphadenectomy on locally advanced Siewert type Ⅱ and Ⅲ adenocarcinoma of esophagogastric junction with a tumor diameter ≥4 cm: a five-year survival analysis].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  5. [Analysis of characteristics and trends of randomized controlled trials of gastric cancer between 2000 and 2019].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  6. [Quality of life after totally laparoscopic versus laparoscopic-assisted total gastrectomy: a retrospective cohort study with propensity score matching].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Technical difficulties and countermeasures of digestive tract reconstruction in robotic radical gastrectomy for gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Establishment of artificial neural network model for predicting lymph node metastasis in patients with stage Ⅱ-Ⅲ gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryRCT
All its trials on ClinicalTrials.gov, any status73
  1. Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT07314203Lead (inferred)Phase 3Start 2026-12
  2. Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction AdenocarcinomaEnrolling by invitationNCT07356466Lead (inferred)Early phase 1Start 2025-05
  3. Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)RecruitingNCT06945718Lead (inferred)Start 2025-05
  4. 3D-4K-ICG Laparoscopic Gastrectomy for Gastric CancerRecruitingNCT06161207Lead (inferred)Phase 3Start 2023-01
  5. A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal TumorsRecruitingNCT05938309Lead (inferred)Start 2023-05
  6. A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma PatientsRecruitingNCT06277024Lead (inferred)N/AStart 2023-01
  7. Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Lead (inferred)Phase 2Start 2022-09
  8. Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric CancerRecruitingNCT05618821Lead (inferred)Phase 2Start 2022-06
  9. the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric CancerNot yet recruitingNCT05235932Lead (inferred)N/AStart 2022-02
  10. Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different ImmunotypesNot yet recruitingNCT05610332Lead (inferred)Phase 3Start 2022-11
  11. Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric CancerNot yet recruitingNCT04795063Lead (inferred)N/AStart 2021-03
  12. Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable SiteRecruitingNCT03716089Lead (inferred)Start 2018-10
  13. Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive GastrectomyActive, not recruitingNCT06938139Lead (inferred)Start 2025-03
  14. Model for Prognosis of Elderly Gastric Cancer PatientsCompletedNCT06393153Lead (inferred)Start 2024-01
  15. Prediction Model for Advanced Gastric Cancer in ElderlyCompletedNCT06467591Lead (inferred)Start 2024-01
  16. Trajectory of Body Composition Identifies LAGC with Cachexia Following NACTCompletedNCT06716593Lead (inferred)Start 2024-09
  17. Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGCCompletedNCT06696963Lead (inferred)Start 2024-03
  18. Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant TherapyCompletedNCT06573307Lead (inferred)Start 2024-06
  19. A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric AdenocarcinomaCompletedNCT06337266Lead (inferred)Start 2023-01
  20. Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant ChemotherapyCompletedNCT06689462Lead (inferred)Start 2023-12
  21. Predict 5-Year Survival in Elderly Gastric CancerCompletedNCT06208046Lead (inferred)Start 2023-07
  22. Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant ChemotherapyStatus unknownNCT06277453Lead (inferred)Start 2023-01
  23. Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence RiskCompletedNCT06337279Lead (inferred)Start 2022-12
  24. Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.CompletedNCT06376773Lead (inferred)Start 2022-06
  25. Questionnaire Survey of the Advanced Training Program for Laparoscopic Radical GastrectomyCompletedNCT05219539Lead (inferred)Start 2021-11
  26. Effect of Gastric Cancer Specialist Training Program in Laparoscopic Gastric Cancer Surgery(STP-LRG-1)CompletedNCT05585437Lead (inferred)Start 2021-11
  27. Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric CancerActive, not recruitingNCT04593615Lead (inferred)N/AStart 2020-11
  28. Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCompletedNCT04195828Lead (inferred)Phase 2Start 2020-06
  29. Trials Comparing of HD Versus 4K Laparoscopy for Gastric CancerStatus unknownNCT04010006Lead (inferred)N/AStart 2019-07
  30. The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric CancerStatus unknownNCT06235164Lead (inferred)Start 2019-01
  31. Clinical Efficacy Between Robotic and Laparoscopic Total Gastrectomy in Patients With Clinical Stage I Gastric CancerStatus unknownNCT03524300Lead (inferred)N/AStart 2018-06
  32. The Effect of Postoperative Referred Pain in the Left Shoulder on Short-term Outcomes for Laparoscopic GastrectomyStatus unknownNCT03482609Lead (inferred)Start 2018-07
  33. Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.CompletedNCT06706466Lead (inferred)Start 2018-01
  34. Robotic Total Gastrectomy for Locally Advanced Proximal Gastric CancerCompletedNCT03524287Lead (inferred)N/AStart 2018-03
  35. Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric CancerStatus unknownNCT03192735Lead (inferred)Phase 2Start 2017-09
  36. Clinical Outcomes of Laparoscopic D1 Versus D2 Lymphadenectomy for Elderly Patients With Advanced Gastric CancerStatus unknownNCT03290209Lead (inferred)Phase 2Start 2017-08
  37. Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric CancerCompletedNCT03313700Lead (inferred)N/AStart 2017-09
  38. Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node DissectionCompletedNCT03050879Lead (inferred)Phase 2Start 2017-10
  39. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Lead (inferred)Phase 2Start 2016-09
  40. The Safety, Feasibility and Oncological Outcomes of Laparoscopic Completion Total Gastrectomy for Remnant Gastric CancerStatus unknownNCT02792881Lead (inferred)N/AStart 2016-06
  41. The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic GastrectomyStatus unknownNCT02930278Lead (inferred)Start 2016-09
  42. Assessment of Robotic Versus Laparoscopic Gastrectomy for GC Patients With Intraoperative Technical ComplexityCompletedNCT06752538Lead (inferred)Start 2016-08
  43. Learning Curve and Optimization of Robotic GastrectomyCompletedNCT05715775Lead (inferred)Start 2016-08
  44. The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic GastrectomyStatus unknownNCT02930291Lead (inferred)Start 2016-09
  45. Prospective Study on Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery for Distal Gastric CancerStatus unknownNCT02289183Lead (inferred)N/AStart 2015-01
  46. Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching AnalysisCompletedNCT06941168Lead (inferred)Start 2015-01
  47. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric CancerStatus unknownNCT02333721Lead (inferred)N/AStart 2015-01
  48. A Recurrence Nomogram for Hepatoid Adenocarcinoma of the StomachCompletedNCT05274464Lead (inferred)Start 2004-04
  49. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  50. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  51. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric CancerRecruitingNCT07029269Study sitePhase 3Start 2025-06
  52. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  53. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  54. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  55. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  56. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  57. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  58. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  59. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  60. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  61. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  62. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  63. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  64. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  65. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  66. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  67. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  68. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  69. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  70. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  71. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  72. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  73. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Fuzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. USP17 is upregulated in osteosarcoma and promotes cell proliferation, metastasis, and epithelial-mesenchymal transition through stabilizing SMAD4.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 13 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 2.5%.

Papers led
13
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 4420232024: 4420242025: 222025

6 hospitals in Fuzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05938309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  2. Recruiting
    Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
    Phase
    Not given
    Started
    2018-10
    Registry
    NCT03716089

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led13
  1. Treatment research after failure of fourth-line standard therapy for advanced gastrointestinal stromal tumors: A review.2025Cancer
  2. Radiomics models with baseline MRI and clinical data to predict target therapy response and high-risk mortality in metastatic GIST.2025Scientific reports
  3. Feasibility and efficacy of minimally invasive limited resection for primary duodenal gastrointestinal stromal tumors: a retrospective cohort study.2024BMC surgery
  4. Reply to comment on predicting the risk stratification of gastrointestinal stromal tumors using machine learning‑based ultrasound radiomics.2024Journal of medical ultrasonics (2001)
  5. Predicting the risk stratification of gastrointestinal stromal tumors using machine learning-based ultrasound radiomics.2024Journal of medical ultrasonics (2001)
  6. Deep Learning-Based Segmentation and Risk Stratification for Gastrointestinal Stromal Tumors in Transabdominal Ultrasound Imaging.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  7. Panniculitis during avapritinib therapy for gastrointestinal stromal tumour.2023European journal of dermatology : EJD
  8. Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features.2023La Radiologia medicaRCT
  9. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.2023The oncologist
  10. Use of a Convolutional Neural Network to Predict the Malignant Potential of Gastrointestinal Stromal Tumors in Transabdominal Ultrasound Images: Visualization of the Focus of the Prediction Model.2023Ultrasound in medicine & biology
  11. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.2022La Radiologia medicaRCT
  12. Application of ultrasonography in predicting the biological risk of gastrointestinal stromal tumors.2022Scandinavian journal of gastroenterology
  13. Dynamic survival analysis of gastrointestinal stromal tumors (GISTs): a 10-year follow-up based on conditional survival.2021BMC cancer
Chinese-language papers (not in the count)1
  1. [Optimal duration of preoperative imatinib therapy in locally advanced gastrointestinal stromal tumors].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)4
  1. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.2017Journal of cancer research and clinical oncology
  2. Can laparoscopic surgery be applied in gastric gastrointestinal stromal tumors located in unfavorable sites?: A study based on the NCCN guidelines.2017Medicine
  3. Short- and Long-Term Outcomes of Laparoscopic Versus Open Resection for Gastric Gastrointestinal Stromal Tumors: A Propensity Score-Matching Analysis.2016Medicine
  4. [Impact of laparoscopic surgery on efficacy in the treatment of gastrointestinal stromal tumors in different anatomical locations].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status6
  1. Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GISTNot yet recruitingNCT05970900Lead sponsorPhase 3Start 2023-10
  2. A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal TumorsRecruitingNCT05938309Lead (inferred)Start 2023-05
  3. Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable SiteRecruitingNCT03716089Lead (inferred)Start 2018-10
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  5. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  6. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

9 hospitals in Fuzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

2 hospitals in Fuzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  2. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  3. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  4. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  5. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBispecific & antibody drugsStem cell transplantRelapse & resistance
Papers it led6
  1. Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation.2026Journal of chemotherapy (Florence, Italy)
  2. USP4, Transcriptionally Activated by MEF2A, Protects Multiple Myeloma Cells From Endoplasmic Reticulum Stress-Mediated Apoptosis via Repressing NR4A1 Ubiquitination.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.2025Journal of hematology & oncologyFree full text
  4. Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.2025Scientific reportsFree full text
  5. Efficacy and safety of tandem autologous stem cell transplantation in multiple myeloma: a retrospective single-center analysis.2023Chinese medical journalFree full text
  6. Modified Culture System and Combination of FICTION Could Increase the Detection Rate of Abnormalities in Multiple Myeloma.2021Annals of clinical and laboratory science
Chinese-language papers (not in the count)3
  1. [The Value of T Cell subsets and Cytokine Levels Changes in the Clinical Diagnosis, Treatment and Prognosis Evaluation of Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  2. [Effect of miR-203/CREB1 Signaling Regulation Mediated by DNA Methylation on the Proliferation and Apoptosis of Multiple Myeloma Cells].2022Zhongguo shi yan xue ye xue za zhi
  3. [Expression and Clinical Significance of Heat Shock Protein 90 in Multiple Myeloma Patients].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status18
  1. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  2. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  4. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  5. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  7. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  8. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  9. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  10. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  11. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  12. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Study sitePhase 2Start 2019-01
  13. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  14. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  15. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  16. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  17. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  18. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

2 hospitals in Fuzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildren
Departments in papersPediatrics
Papers it led4
  1. UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia.2025Cell death & diseaseFree full text
  2. Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.2025Pharmacogenetics and genomicsFree full text
  3. Long Non-Coding RNA RP11-252C15.1 Is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-Cell Precursor Acute Lymphoblastic Leukemia.2024Acta haematologica
  4. Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.2024BMC cancerFree full text
Chinese-language papers (not in the count)2
  1. [Clinical Characteristics and Prognosis of Children with Hypodiploid B-cell Precursor Acute Lymphoblastic Leukemia].2024Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].2024Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status6
  1. CART-19 Cells For R/R B-ALLStatus unknownNCT03391739Lead (inferred)Phase 2/Phase 3Start 2016-01
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  3. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  5. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01
  6. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Fuzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesClonal evolution & PNH
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 6 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 2.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 222025

3 hospitals in Fuzhou for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07416604

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led6
  1. Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia.2025Annals of hematology
  2. Development and validation of an innovative approach to estimating FVIII levels and designing personalised doses in the prophylactic treatment of haemophilia A: based on the principle of the two-compartment model.2025BMJ open
  3. Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.2024International immunopharmacology
  4. Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice.2024International immunopharmacology
  5. Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors.2024Journal of thrombosis and haemostasis : JTH
  6. Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications.2022Frontiers in immunology
Chinese-language papers (not in the count)2
  1. [RNA Sequencing Reveals Molecular Alternations of Splenocytes Associated with Anti-FⅧ Immune Response in Hemophilia A Murine Model].2025Zhongguo shi yan xue ye xue za zhi
  2. [Analysis of APTT Mixing Test Results in Factor Ⅷ Inhibitor-Positive Hemophilia Patients].2023Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)3
  1. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.2017Journal of thrombosis and haemostasis : JTH
  2. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.2016Blood
  3. [Pathogenetic mechanism for a female patient with hemophilia A].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
All its trials on ClinicalTrials.gov, any status11
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Study sitePhase 3Start 2026-04
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  4. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  5. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  6. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  7. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  8. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  9. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionStatus unknownNCT03747653Study siteStart 2019-03
  10. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  11. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Fuzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Fuzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

2 hospitals in Fuzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 4 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 112025

1 hospital in Fuzhou for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryChildren
Departments in papersNeurosurgeryRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

4 hospitals in Fuzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Fuzhou for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 11 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.4%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 1120232024: 2220242025: 332025

5 hospitals in Fuzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology
Papers it led11
  1. Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis.2025Annals of medicine
  2. Structural atrophy and functional disturbance in the thalamic nuclei of patients with amyotrophic lateral sclerosis.2025Brain research bulletin
  3. Soma and neurite density imaging detects brain microstructural impairments in amyotrophic lateral sclerosis.2025European journal of radiology
  4. Neurite orientation dispersion and density imaging quantifies microstructural impairment in the thalamus and its connectivity in amyotrophic lateral sclerosis.2024CNS neuroscience & therapeutics
  5. Eomesodermin expression in CD4+T-cells associated with disease progression in amyotrophic lateral sclerosis.2024CNS neuroscience & therapeutics
  6. Corticospinal fibers with different origins impair in amyotrophic lateral sclerosis: A neurite orientation dispersion and density imaging study.2023CNS neuroscience & therapeutics
  7. Characterizing Sensorimotor-Related Area Abnormalities in Amyotrophic Lateral Sclerosis: An Intravoxel Incoherent Motion Magnetic Resonance Imaging Study.2022Academic radiology
  8. Novel FUS mutation Y526F causing rapidly progressive familial amyotrophic lateral sclerosis.2021Amyotrophic lateral sclerosis & frontotemporal degeneration
  9. Dynamic Changes in Functional Network Connectivity Involving Amyotrophic Lateral Sclerosis and Its Correlation With Disease Severity.2021Journal of magnetic resonance imaging : JMRI
  10. White matter microstructural impairments in amyotrophic lateral sclerosis: A mean apparent propagator MRI study.2021NeuroImage. Clinical
  11. Novel TARDBP missense mutation caused familial amyotrophic lateral sclerosis with frontotemporal dementia and parkinsonism.2021Neurobiology of aging
Earlier papers (2016–2020)9
  1. Brain Cortical Complexity Alteration in Amyotrophic Lateral Sclerosis: A Preliminary Fractal Dimensionality Study.2020BioMed research international
  2. Abnormal cerebral microstructures revealed by diffusion kurtosis imaging in amyotrophic lateral sclerosis.2020Journal of magnetic resonance imaging : JMRI
  3. Familial flail leg ALS caused by PFN1 mutation.2020Journal of neurology, neurosurgery, and psychiatry
  4. Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia.2019Annals of clinical and translational neurology
  5. Brain white matter abnormalities and correlation with severity in amyotrophic lateral sclerosis: An atlas-based diffusion tensor imaging study.2019Journal of the neurological sciences
  6. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.2017Journal of neurology, neurosurgery, and psychiatry
  7. H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  8. Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  9. The distinctive genetic architecture of ALS in mainland China.2016Journal of neurology, neurosurgery, and psychiatry
All its trials on ClinicalTrials.gov, any status2
  1. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALSNot yet recruitingNCT07169175Study sitePhase 1/Phase 2Start 2025-12
  2. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral SclerosisNot yet recruitingNCT06645197Study siteEarly phase 1Start 2024-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Antisense Oligonucleotide for Spinal Muscular AtrophyStatus unknownNCT05187260Study siteStart 2022-01
  2. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Fuzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Fuzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Fuzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

福建医科大学附属协和医院

Fujian Medical University Union Hospital

福州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
FUjian Medical University Union Hospital; Union Hospital

Suggest a correctionDownload the data